Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma
10.3760/cma.j.issn.1007-3418.2019.11.005
- VernacularTitle: 肝细胞癌靶向治疗和免疫治疗的临床进展
- Author:
Dezhi ZHANG
1
;
Junqi NIU
Author Information
1. The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Targeted therapy;
Immunotherapy
- From:
Chinese Journal of Hepatology
2019;27(11):834-837
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) has a high incidence and mortality rate in China, and is the worst-than-expected cancer management disease in all provinces of the country. In recent years, systemic drug therapy for HCC has developed rapidly, especially molecular targeted drugs and immune checkpoint blocker being the most prominent. Molecular targeted drugs and immune checkpoint blocker have achieved some progress in the treatment of advanced HCC, but they still have many problems and challenges. This paper briefly introduces the latest advances of drug therapy for advanced HCC.
